Trulicity

Selected form

Dulaglutide

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trulicity

Property	Description
Active ingredient	Dulaglutide (INN)
Form	Aqueous solution for injection in a pre-filled pen
Pharmacological class	GLP-1 receptor agonist (Incretin mimetic)
Common purpose	Improve metabolic control and stabilize blood sugar
Origin	Biologic drug, produced via recombinant DNA technology
Manufacturer/Status	Eli Lilly and Company, Prescription-only (Rx)

Trulicity: Defining the GLP-1 Receptor Agonist

Trulicity is the commercial name for the prescription-only medication containing the active ingredient Dulaglutide. It is classified as a Glucagon-like peptide-1 (GLP-1) receptor agonist, a specialized biologic drug that mimics the action of a natural gut hormone to regulate metabolism. Unlike traditional small-molecule drugs, Dulaglutide is a complex peptide molecule produced using recombinant DNA technology. Its classification within the Incretin mimetics signifies its mechanism of leveraging the body’s own signaling system for metabolic management.

What is the Form and Composition of Dulaglutide?

The medicine is supplied as a clear, colorless aqueous solution for injection, contained within a ready-to-use pre-filled, single-dose pen designed for subcutaneous injection. The unique structural feature of the Dulaglutide molecule—a GLP-1 analogue sequence fused to a modified human immunoglobulin G4 (IgG4) fragment—is a key differentiating factor. This specific engineering gives the drug a prolonged half-life, supporting a once-weekly administration schedule, distinguishing it from older, daily-injected incretin-based therapies.

What is the General Purpose of This Type of Medicine?

The overall purpose of Trulicity is to provide advanced metabolic support for achieving stable and balanced blood sugar levels (glycemic control). As a GLP-1 receptor agonist, the drug facilitates the release of insulin from the pancreas only when blood sugar is elevated (a glucose-dependent mechanism), and also contributes to slowing down digestion. This dual action is designed to reduce elevated sugar levels both before and after meals. This coordinated activity is essential for the long-term stabilization of blood sugar and management of chronic metabolic conditions.

What side effects are possible with Trulicity?

Possible Side Effects and Safety Information

Adverse reactions associated with the active ingredient Dulaglutide are categorized by frequency and system-organ class, based strictly on official government regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented effects are associated with the Gastrointestinal disorders system and are typically observed more frequently at the beginning of treatment, generally decreasing over time with continued use.

Very Common Reactions: Nausea and Diarrhea are classified as very common.
Common Reactions: Vomiting, abdominal pain, decreased appetite, dyspepsia, constipation, and Gastroesophageal reflux disease (GERD) are listed as common.
Uncommon/Rare Reactions: Less frequent reactions include cholelithiasis (gallstones), increased heart rate, and injection site reactions. Rare events include severe hypersensitivity reactions such as anaphylactic reaction and angioedema.

Serious Adverse Reactions and Safety Constraints

Official prescribing information documents specific, clinically significant safety concerns. The potential for Acute Pancreatitis is a documented serious adverse reaction. Additionally, reports of Acute Kidney Injury have occurred, often associated with severe gastrointestinal events that can lead to fluid loss.

Furthermore, the use of this medication is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Specific regulatory notes address patients with severe renal impairment, who may experience an increased frequency of certain gastrointestinal adverse events, and note that the potential for delayed gastric emptying may alter the absorption of other oral medications.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation describes Dulaglutide overdose based on clinical experience with supratherapeutic doses, resulting primarily in an exaggeration of known pharmacological effects. All information presented here is derived strictly from government-authorized prescribing information.

Documented Manifestations and Outcomes

Classification	Officially Documented Findings
Clinical Presentations	Severe nausea and severe vomiting are the most prominent manifestations reported. The occurrence of hypoglycemia (low blood sugar) is a recognized potential physiological abnormality.
Severe Outcomes	Protracted severe gastrointestinal losses carry the documented risk of dehydration and resulting fluid and electrolyte imbalance.

Required Emergency Actions

Action Area	Official Regulatory Statement
Immediate Help	Individuals must seek immediate medical attention following a suspected overdose. Urgent care is required due to the potential for severe fluid loss and sustained hypoglycemia.
Management Note	No specific antidote is known for Dulaglutide overdose. Management is restricted to symptomatic and supportive treatment based on the patient’s clinical condition.
Monitoring	A prolonged period of clinical observation is necessary due to the drug’s extended half-life, ensuring symptoms resolve and metabolic stability is achieved.

Therapeutic Uses of Trulicity

What Trulicity Treats: Main Uses and Benefits

The primary therapeutic use of this medication is relevant for the management of Type 2 Diabetes Mellitus (T2DM). The medication is commonly used to help with addressing the chronic pattern of inadequately controlled high blood sugar (hyperglycemia) in adults and pediatric patients aged 10 and older. This medication is applied in clinical settings for three key therapeutic areas: assisting with stable glycemic control, reducing the potential for major adverse cardiovascular events, and providing supportive metabolic health.

“This treatment is relevant for chronic metabolic conditions where symptoms are linked to organ-specific functional stress and require long-term support.”

The primary benefit may assist with achieving more stable glycemic control, which helps reduce long-term markers like HbA1c and supports improved daily glucose fluctuations. Furthermore, for high-risk patients, it plays a role in managing reduced cardiovascular risk, particularly regarding non-fatal heart attack or stroke, and may assist with a supportive benefit for body weight reduction. The medication provides support that helps ease the overall symptom load and assists with maintaining functional stability.

Quick Fact: Supports Management of Systemic Imbalance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Trulicity

Category	Official Regulatory Statement
Populations Allowed	Adults with Type 2 Diabetes Mellitus (T2DM). Pediatric patients aged 10 years and older with T2DM.
Absolute Contraindications	Patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Individuals with a prior serious hypersensitivity reaction to dulaglutide or any components.
Use Not Recommended	Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. Individuals with severe gastrointestinal disease, including severe gastroparesis, as use has not been studied. Use is not recommended during pregnancy or lactation.
Condition-Specific Cautions	Renal Impairment: No dosage adjustment is required for mild, moderate, or severe renal impairment; however, experience is very limited in End-Stage Renal Disease (ESRD). The drug has not been studied in patients with a history of pancreatitis.

Official Eligibility Structure: Regulatory documents define the eligible population as those with T2DM who are 10 years of age or older. The use is unequivocally prohibited in populations with a history of MTC, MEN 2, or known serious allergy. Limitations are also placed on eligibility due to physiological states such as ESRD and pregnancy, where use is officially not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of dulaglutide is primarily defined by its effects on blood glucose levels and gastrointestinal function, as documented in regulatory information.

Pharmacodynamic Interactions

Co-administration with other medications that lower blood glucose levels, such as insulin and insulin secretagogues (e.g., sulfonylureas), results in an additive pharmacodynamic effect. This combination is officially documented as increasing the risk of hypoglycemia.

Pharmacokinetic Interactions

Dulaglutide may cause a pharmacokinetic interaction by delaying gastric emptying. This action has the potential to alter the rate of absorption and the peak concentration (Cmax) of orally administered medications.

However, testing with several widely used oral medicines, including Atorvastatin, Digoxin, Lisinopril, Metoprolol, Paracetamol, and Warfarin, demonstrated that while changes in the rate of absorption may occur, the overall exposure (AUC) was not clinically relevant, and regulatory documents state no dose adjustment is necessary for these specific drugs. Dulaglutide is a peptide and is eliminated via general protein catabolism, meaning no specific clinically relevant interactions involving the cytochrome P450 (CYP) enzyme system are documented.

Administration Requirements

When dulaglutide is used concurrently with injectable insulin, the two medicines must not be mixed in the same syringe or pen and must be administered as separate injections at separate sites.

Mechanism of Action

Trulicity (dulaglutide) functions as a long-acting Glucagon-like Peptide-1 (GLP-1) receptor agonist. It selectively binds to and activates the GLP-1 receptor, a G protein-coupled receptor found on the surface of various cells, notably the pancreatic beta cells and other tissues in the gastrointestinal tract and brain.

Activation of the GLP-1 receptor initiates a downstream signaling cascade involving the enzyme adenylyl cyclase, which catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP levels serve as a secondary messenger to activate Protein Kinase A (PKA). Within the pancreatic beta cell, this pathway promotes glucose-dependent insulin secretion by facilitating the closure of K ATP channels, leading to membrane depolarization and subsequent influx of calcium ions, a prerequisite for insulin granule exocytosis.

Concurrently, dulaglutide modulates alpha cell activity to cause a reduction in glucagon secretion and induces a systemic physiological effect of delayed gastric emptying. These combined actions result in an overall sustained modulation of circulating glucose and energy substrate absorption.

Dosage and Administration Information

How Trulicity is Used: Administration Guidelines

Administration Scope

The medicine is administered exclusively by subcutaneous (SC) injection using a pre-filled, single-dose pen. It must not be administered via the intravenous or intramuscular route. The overall use pattern is characterized by once-weekly administration, which can occur at any time of day, with or without food.

Standard Dosing and Schedule

The standard adult regimen is initiated with a starting dose of 0.75 mg once weekly. The dose may be systematically escalated (titrated) in 1.5 mg increments, reaching strengths of 1.5 mg, 3 mg, and up to the maximum recommended dose of 4.5 mg once weekly. To support this long-term use, any dose increase should only occur after the patient has remained on the current dosage for a minimum of four weeks.

Procedural and Population Rules

For pediatric patients aged 10 and older, the maximum recommended dose is 1.5 mg once weekly. For older adults or patients with renal or hepatic impairment, dose adjustments are generally not specified for these populations. Procedurally, the injection site must be rotated weekly among the abdomen, thigh, or upper arm.

Instructions for a missed dose are time-dependent: if the next scheduled dose is 72 hours or more away, the missed dose should be taken as soon as possible. If less than 72 hours remain, the missed dose must be skipped, and the regular schedule resumed on the appointed day.

Recent Clinical Evidence

Research evidence / Overview of studies for Trulicity

This section provides an overview of the types of official research conducted to evaluate the use of dulaglutide (Trulicity), describing the study designs and where research gaps may exist.

Evidence Related to Blood Sugar Measurements in Adults

Research exploring dulaglutide for use in relation to blood sugar levels in adults with Type 2 Diabetes Mellitus (T2DM) was evaluated in many large Randomized Controlled Trials (RCTs), known as the AWARD program. These studies tracked outcomes such as the long-term blood sugar marker Glycated Hemoglobin (HbA1c) and changes in fasting and post-meal glucose concentrations. Findings describe patterns observed in these trials across different treatment scenarios.

Evidence Related to Cardiovascular Outcomes

Research has explored long-term outcomes related to the heart and blood vessels using a single, dedicated Cardiovascular Outcome Trial (CVOT), the REWIND trial. This study was conducted in adults with T2DM, including those with established cardiovascular disease or multiple cardiovascular risk factors. The primary outcome measured was the time to first occurrence of a composite of Major Adverse Cardiovascular Events (MACE), such as cardiovascular death, non-fatal heart attack, and non-fatal stroke. Findings indicate patterns related to the MACE endpoint over the study duration.

Long-Term Evidence and Research Gaps

The core clinical research includes intermediate-term follow-up (up to two years) for blood sugar measurements, while the CVOT extended to a median of 5.4 years. Research has explored the consistency of measured changes over these intervals. Specific research was also evaluated for its use in youth and adolescents (ages 10 and older) in a smaller, short-term RCT.

However, limitations and research gaps exist: Data for certain groups remain insufficient, and the primary RCT results apply only to the specific populations studied, meaning the applicability to all T2DM patients seen in routine clinical practice may be limited. Research does not determine whether an individual will respond similarly to the group averages described in the studies.

Frequently Asked Questions (FAQ)

Common questions about Trulicity (FAQ)

Q: What are the severe side effects I need to watch out for?

Official regulatory documents indicate that serious adverse reactions that have been reported include acute pancreatitis (inflammation of the pancreas) and acute kidney injury. The kidney issues are sometimes associated with severe gastrointestinal events that can lead to fluid loss. Regulatory warnings indicate the medicine is not for use in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Q: Can I use Trulicity if I have a history of cancer in my family?

Regulatory warnings state the medicine is contraindicated in the presence of a personal or family history of a specific thyroid cancer called Medullary Thyroid Carcinoma (MTC). This also applies to a condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The official label does not provide specific information regarding a family history of other types of cancer.

Q: What is the maximum dose for a 12-year-old child?

Official prescribing information states that for pediatric patients aged 10 and older, the maximum recommended dosage is 1.5 mg once weekly. The official label specifies a lower starting dose, and the maximum is reached after a period of dose escalation, if appropriate.

Q: How should I travel with my Trulicity pen (e.g., on a plane)?

Official instructions specify that the pen must be protected from freezing and excessive heat. The product's stability limits allow for storage at room temperature (up to 30 C or 86 F) for a single period of up to 14 days. A pen that has been stored outside of refrigeration for longer than this 14-day limit should not be used, according to product information.

Q: What should I do if the medicine in the pen looks cloudy or has particles?

The medicine is supplied as a clear, colorless solution for injection. If the solution appears to be cloudy, discolored, or contains particles, official instructions indicate that it should not be administered and must be discarded. This is important to ensure the medicine's integrity.

Q: Can I take an oral contraceptive pill while on Trulicity?

Drug interaction studies were conducted with an oral contraceptive containing ethinyl estradiol and norgestimate. The results showed no clinically relevant change in the overall exposure of the contraceptive components. Consequently, the official label does not recommend a dose adjustment for the specific oral contraceptive that was studied.

How should Trulicity be stored and disposed of?

How to Store and Dispose of Trulicity (Dulaglutide)

Official regulatory guidelines define precise conditions for storing and discarding the Trulicity pre-filled pen to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store in the refrigerator between 2 C and 8 C (36 F and 46 F).
Freezing	Do not freeze. The pen must be discarded if it has been frozen.
Protection	Keep in the original carton to protect the solution from light.
Stability Limit	May be stored at room temperature (up to 30 C or 86 F) for a single period of up to 14 days, after which it must be discarded.
Child Safety	Store out of the sight and reach of children.

Disposal Instructions

Used pens must be discarded as medical sharps waste. Immediately place the pen in an FDA-cleared sharps disposal container after use. The pen and sharps container must not be thrown into household trash or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.